Clinical Trials Browser

Phase 3 × ON 01910 × Other hematologic neoplasm × Clear all

NCT01928537 2020-06-30

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

Phase 3 Completed

Classical hematologyMyeloidOther hematologic neoplasm

Cytopenia, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic